ALASKA – After months of research and deliberation, the Alaska Legislative Task Force for the Regulation of Psychedelic Medicines has recommended that Alaska prepare to legalize psychedelic therapy once the Food and Drug Administration (FDA) authorizes substances like psilocybin and MDMA for medical use. This significant development in Alaska’s approach to mental health treatment, was reported on Marijuana Moment.
The task force is recommending that the state move forward with plans to provide regulated access to psychedelics if the federal Food and Drug Administration (FDA) authorizes the medical use of substances like psilocybin and MDMA.
After about a year of work studying the issue under a law enacted in 2024, the Alaska Legislative Task Force for the Regulation of Psychedelic Medicines last week unveiled its findings and recommendations.
“Alaska has some of the highest rates in the nation of domestic violence survivors and combat veterans who experience PTSD, and many of these Alaskans continue to struggle with traditional treatments,” Sen. Forrest Dunbar (D), co-chair of the task force, said in a press release.
“Our approach to these new medical therapies needs to be properly and independently evaluated to ensure that if the legislature were to make policy changes, we do so with empirical data in a properly controlled environment,” the senator said.
Findings Revealed In The Panel’s Report
The panel’s report lists a series of findings, informed by a review of scientific literature and expert testimony. That includes findings that certain psychedelics do, in fact, possess “potential therapeutic uses,” and “there is particular focus on use of these therapies for veterans, survivors of assault and interpersonal violence, and others with treatment-resistant post-traumatic stress disorder (PTSD).”
Members emphasized the importance of administering psychedelic therapies in a collaborative way with “multiple provider types” to deliver a comprehensive treatment approach, rather than leaving it up to the individual patient to navigate.
Chief among its recommendations, the task force said: “If and when psychedelic medicine therapies are FDA approved, the state should take action to allow for their use in Alaska, rather than prohibiting use.”
Alaska regulators should also identify clinical working groups “whose function is to regularly review updated studies and the evidence base to make recommendations, and rely on these entities to provide ongoing guidance on use of these therapies,” it said.
“To the extent possible, reserve use of state statute for broad enabling language and key components of a regulatory structure, and leave most regulatory decisions to the relevant boards and agencies,” another recommendation states. “Regulations still require robust public process in order to be adopted, but can be updated or modified more predictably and easily than statute changes, which require an act of the Legislature.”
“It is likely that appropriate parameters for use of these therapies will change over time, as the evidence base matures and FDA approval may be granted for multiple therapies,” it said.
Measures To Be Done Should Approval Be Granted
Should FDA proceed with approving any given psychedelic for medical use, the panel said the Alaska State Medical Board should update its guidance for prescribing controlled substances to incorporate the novel therapies.
Also if FDA approves psychedelic medicines, and the Drug Enforcement Administration (DEA) follows suit by federally rescheduling substances like psilocybin, Alaska should “fully mirror federal scheduling and Risk Evaluation and Mitigation Strategies (REMS) without adding duplicative or conflicting state rules, and follow any rules regarding whether DEA licensure is required for prescribers,” the report says.
“This approach respects federal science and streamlines access for patients and providers,” it continues.
Across the United States, psychedelics are increasingly being studied for their potential to address conditions that traditional therapies often fail to resolve. Alaska, a state with particularly high rates of trauma among veterans and survivors of violence, is now considering how to responsibly integrate these therapies into its healthcare system.
